Your browser doesn't support javascript.
loading
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Bellon, Jennifer R; Guo, Hao; Barry, William T; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew; Wolff, Antonio C; Carey, Lisa A; Overmoyer, Beth A; Partridge, Ann H; Hudis, Clifford A; Krop, Ian; Burstein, Harold J; Winer, Eric P; Tolaney, Sara M.
Afiliação
  • Bellon JR; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA, USA. Jennifer_bellon@dfci.harvard.edu.
  • Guo H; Department of Statistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Barry WT; Department of Statistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dang CT; Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical Center, New York, NY, USA.
  • Yardley DA; Department of Medical Oncology, Sarah Cannon Cancer Center, Nashville, TN, USA.
  • Moy B; Department of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Marcom PK; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Durham, NC, USA.
  • Albain KS; Division of Hematology/Oncology, Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
  • Rugo HS; Department of Medicine, Division of Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
  • Ellis M; Department of Medical Oncology, Baylor Clinic-Lester and Sue Smith Breast Center, Houston, TX, USA.
  • Wolff AC; Department of Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA.
  • Carey LA; Department of Medical Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Overmoyer BA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Partridge AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hudis CA; Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical Center, New York, NY, USA.
  • Krop I; American Society of Clinical Oncology, Alexandria, VA, USA.
  • Burstein HJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Cancer Res Treat ; 176(2): 303-310, 2019 Jul.
Article em En | MEDLINE | ID: mdl-31004299
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Paclitaxel / Receptor ErbB-2 / Trastuzumab / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Paclitaxel / Receptor ErbB-2 / Trastuzumab / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article